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ABSTRACT

Angiotensin II (ang II) is a vasoactive hormone derived from the renin

angiotensin system (RAS), which regulates blood pressure and fluid balance in the body.
Ang II effects are mediated via two major receptors: type 1 (AT 1) and type 2 (AT2).

Adipocytes contain a local RAS in which ang II upregulates adipogenesis, fatty acid and
triglyceride synthesis primarily mediated via the AT2 receptor in cultured adipocytes.

Preliminary studies from our lab tested the importance of AT2 receptors in vivo and

reported a decrease in adiposity by AT2 antagonism in the lean, but not the genetically

obese db/db mouse. To further explore these effects, we used another genetic model of

obesity (ob/ob) and diet-induced obese (DIO) mice and treated them for 2-3 weeks with

the AT2 receptor antagonist, PD 123,319. Body weight, fat pad weight and plasma

glucose, leptin and insulin levels and fatty acid synthase (FAS) and glycerol-3-phosphate
dehydrogenase (GPDH) activity were measured. Consistent with previous findings in

lean mice, the AT2 antagonist decreased abdominal fat pad weight in ob/ob mice and

accelerated weight loss in D10 mice. Also, correlated with these effects, AT2 blockade

decreased FAS activity in ob/ob mice and lowered blood glucose levels in DIO mice. No

significant changes were seen in the other parameters that were measured. In

combination with recently published data, this research further supports the role of the

AT2 receptor in modulating ang II effects on adipocyte metabolism. Defining this role is

crucial in determining and preventing the contribution of adipocyte-derived RAS to
systemic disorders such as obesity-related hypertension.
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CHAPTER I
INTRODUCTION

Sixty-one percent of the adult population in the United States is overweight or
obese (1). This growing number has major public health implications. There are many
chronic health conditions associated with obesity, such as type 2 diabetes, cardiovascular
disease and hypertension (2,3). The increasing prevalence of these and other obesity
related health risks emphasizes the need for understanding the pathogenesis of obesity.
This will allow us to better prevent and treat obesity as a condition and prevent these
associated diseases.
Obesity is a disease characterized by excessive accumulation of adipose tissue in
the body (4). While adipose tissue was once thought of as only a storage depot for
triglycerides, it is now known to also function as a paracrine and endocrine organ (5).
The paracrine function of adipocytes includes regulation of adipose tissue metabolism
and gene expression (6). The endocrine function of adipose tissue includes systemic
effects on blood pressure and kidney homeostasis.
The renin-angiotensin system (RAS) is the major regulator of blood pressure,
fluid and electrolyte balance (7). A local RAS has been identified in adipose tissue (8).
The purpose of this study is to determine how the end product of RAS, angiotensin II,
functions in adipocytes by identifying the receptors mediating its effects in vivo.
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CHAPTER II
LITERATURE REVIEW

Obesity and Hypertension
Obesity

The combined prevalence of overweight and obesity among men and women
between the ages of 20 and 80 is 61 percent (1,9). Not only is the majority of our adults
overweight or obese, but the number of children and adolescents with obesity and type II
diabetes is also increasing (1).
There are several ways to estimate body fat. One of the easiest, most affordable
and least invasive ways is body mass index (BMI). The National Institutes of Health
recommend physicians use BMI when assessing overweight and obesity (Table 1) (2).
BMI is defined as weight (in kg) divided by height in meters squared (in m2).

Table 1. Classification of Overweight and Obesity by BMI.
Obesity Class

BMI (kg/m2)

Underweight

< 18.5

Normal

18.5 - 24.9

Overweight

25.0 - 29.9

Obesity
Extreme Obesity

I

30.0 - 34.9

II

35.0 - 39.9

III

2:40

Health professionals agree that an increase in body weight of twenty percent or
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more is considered a health hazard (10). Health risks of overweight and obesity include
(1-3):

■

■

•
■

■

■

•

■

■

Hypertension

Type 2 diabetes

Coronary heart disease

Stroke

Dyslipidemia

Gallbladder disease
Osteoarthritis

Sleep apnea and respiratory problems
Certain types of cancers

Hypertension, hypercholesterolemia (blood cholesterol over 250 mg/dL) and diabetes

(blood glucose over 126 mg/dL) are more than twice as prevalent in overweight vs. non

overweight individuals (10).

Obesity is a complex and multi-factorial disorder. Genetics, lifestyle and

endocrine disorders all contribute to the epidemic of obesity (1,4,11). The importance of
heredity was shown in a study by Stunkard et al. (12) that found the BMI of adopted

children strongly correlated with the BMis of their biological family members and did

not correlate with the BMIs of their adoptive family. Studies such as this one and others
by Bouchard et al. (13,14) demonstrate the importance of genetics in the pathogenesis
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and etiology of obesity. Researchers are presently working to link the obese phenotype
to the responsible genes.
Lifestyle is a major determinant of obesity, the two main factors being food intake
and physical activity (15). Western lifestyle has changed the energy balance for many
Americans by increasing caloric intake and decreasing physical activity. In many cases
these environmental factors will exacerbate an existing genetic disposition towards
obesity (2).
Obesity due to genetic defects is very rare, but genetic syndromes such as Prader
Willi, Cohen, Borjeson-Forssman-Lehmann that have been identified to cause obesity as
well as other endocrine dysfunctions (16, 17). Prader-Willi syndrome, for example, is
caused by the deletion of multiple genes in close proximity on chromosome fifteen
(18,19). Among other symptoms, a hypothalamic dysfunction causes extreme
hyperphagia (19). This disordered eating is compounded by decreased energy utilization,
making these individuals morbidly obese (20).
While obesity mutations are rare in humans, many animal models of obesity have
been developed based on single gene mutations. Table 2 gives a summary of some major
obesity genes and their effects (11,21-23).
Two mouse mutations commonly used in research are the db/db and ob/ob. The
db/db mouse has a mutation in the gene coding for the leptin receptor while the ob/ob

mouse is leptin-deficient (21). Both cause similar phenotypes in mice (23). These
animals have severe juvenile-onset obesity and exhibit reduced basal metabolic rate,
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Table 2. Genetic mutations resulting in obesity.
Rodent
Human
chromosome chromosome

effects of
mutation
ubiquitous
over-expression
ofagouti

Mutation

Gene product

agouti yellow
(A>')

agouti signaling
protein

2

20

obese (ob)

leptin

6

7

deficiency of
leptin

diabetes (db)

leptin receptor

4

1

defect in leptin
signal

fat (fat)

carbox ypeptidase E

8

4

processing of
prehormone

tubby (tub)

insulin signaling
protein

7

11

undefined

h yperphagia, h yperinsulinemia, insulin resistance, glucose intolerance and diabetes
( 1 1,22,23).
Hypertension
H ypertension is defined as high blood pressure that remains elevated over time
(Table 3) (24,25). It is caused by narrowing ofthe arteries, greater than normal amount
ofblood or the heart beating faster and more forcefully than normal (24). H ypertension
increases stress on the heart and contributes to atheriosclerosis and increases the risk of
heart disease and stroke.
Approximately 50 million adult Americans have high blood pressure and it is
more common in A frican Americans and in the elderly (> 60 years ofage) (24).
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Table 3. Classification of Blood Pressure for Adults ( 2:18 years ofage).

Optimal

Systolic and/or Diastolic
(mm Hg)
<1 20 and <80

Normal

<130 and <85

High-normal

130-13 9 or 85-89

Hypertension
Stage 1

1 40-1 5 9 or 90- 9 9

Stage 2

160-17 9 or 100-10 9

Stage 3

2:180 or 2:110

Individuals who have a high-normal blood pressure are also at risk for hypertension (26).
Others at risk for hypertension are people who are overweight or have a family history of
high blood pressure (24, 25).
Hypertension rates are correlated among family members (27), however the
disease is also multi-factorial. It appears to be polygenic and influenced by the
environment (28).
Health risks associated with hypertension include heart disease, stroke, congestive
heart failure, kidney disease and blindness (24, 25). Hypertension can be prevented or
controlled by the following lifestyle modifications (24, 25):
■

Maintaining a healthy weight

■

Following a healthy eating pattern

■

Being physically active

■

Reducing salt and sodium in the diet
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•

Maintaining adequate intakes of potassium, calcium and
magnesium

•

Limiting alcohol intake

•

Quitting smoking

Another option for controlling hypertension is pharmacological interventions, which will
be discussed in more detail in later sections.

Obesity-related hypertension

Hypertension is the most common co-morbidity associated with obesity (29).
Thirty-six percent of overweight (BMI >25) individuals are hypertensive and over sixty
percent of obese (BMI >35) individuals are hypertensive (30).
Researchers have found a close correlation between increased BMI and increased
rates of hypertension (2,25,31). The prevalence of hypertension in overweight
individuals is 2.9 times higher than in non-overweight individuals (10). When an
individual is diagnosed with hypertension, one of the first recommendations is
maintaining a healthy weight, or weight reduction if the individual is overweight
(24,25,32,33).

Adipose tissue physiology

Adipose tissue is a specialized form of loose connective tissue containing
undifferentiated fibroblasts (preadipocytes), adipocytes, vascular and endothelial cells
(5,34). Fat is stored in the form of triglycerides in the adipocytes. Adipose tissue pads
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and protects organs, insulates the body and stores energy in the form of triglycerides for
use in times of metabolic need (6,10,35). Adipose tissue mass can be increased in two
ways, either by hypertrophy, expanding the size of the adipocyte by storing more
triglycerides, or by hyperplasia, increasing the number of adipocytes (36).
Adipose tissue plays a more complex role in whole body homeostasis than just
energy regulation. Recent research shows that adipose tissue is not only a storage site for
excess energy, but also an endocrine, paracrine/autocrine organ (6,35).
Distribution of fat depots is also an important indicator of disease risk. Different
depots of tissue vary in their level of metabolic activity and metabolic risks (4). Upper
body obesity, known as android obesity, is associated with increased rates of heart
disease, hypertension and type 2 diabetes (4). Excess abdominal fat has a stronger
correlation with coronary heart disease than does thigh or gluteal fat pads (36).
Individuals with lower-body obesity, gynoid obesity, usually have a lower health risks,
however it is often harder to lose this weight (4). These differences could be due to the
composition, amount of blood flow and the metabolic role of each tissue depot, as well as
differences in response to nutritional and hormonal stimuli (4).

Renin-Angiotensin System (RAS)
Systemic RAS

The Renin-Angiotensin System (RAS) is comprised of two enzymatic reactions
that convert angiotensinogen (agt) into angiotensin II (ang II) (Figure 1) (7). Agt is the
only precursor for ang II. RAS is one of the main regulators of blood pressure, plasma
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volume, sympathetic nervous activity and thirst responses (37). The end product, ang II
is a vasoactive hormone that is able to act systemically as well as locally.

Agt is a glycoprotein synthesized by the liver. The liver only stores small

quantities; therefore it is made and released as needed. Renin is a protease synthesized

and stored by the juxtaglomerular apparatus in the afferent arterole of the kidney. Renin
cleaves agt into angiotensin I (ang I), an inactive intermediate in the pathway.

Angiotensin Converting Enzyme (ACE) is a dipeptidyl peptidase that cleaves the

carboxyl-terminal end of ang I and forms the active octapeptide, ang II. There are several
other enzymes that are able to convert agt to ang II (tissue plasminogen activator,

cathepsin G, tonin) and ang I to ang II (chymostatin-sensitive angiotensin II-generating
enzyme, cathepsin G, chymase) (38). The clinical significance of these alternate
pathways is unknown.

Decreased blood pressure and sodium concentration stimulates renin release and

increases ang II production (7). Ang II effects are mediated by specific receptors

throughout the body and uses different signaling mechanisms (39).
RAS-related hypertension

The association between obesity and hypertension has been established for a long

time, but the mechanisms behind this relationship are not completely understood (40).

The RAS pathway is a major determinant in hypertension.
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Ang I I increases sodium concentration, blood volume and blood pressure. This is
accomplished by the actions ofdifferent signaling mechanisms (Figure 1) and at several
sites in the body.
In the kidney, ang I I contracts glomular mesangial cells and smooth muscle in the
efferent arterioles ofthe kidney to decrease filtration (4 1). In the pituitary, ang II
increases the secretion of vasopressin, which is a vasoconstrictor and anti-diuretic (4 1).
In the brain, ang II increases salt appetite and thirst (4 1). Ang II increases heart rate,
constricting blood vessels and smooth muscle cells (4 1). Ang II acts on the glomerulosa
cells of the adrenal cortex that release aldosterone and signal the reabsorption ofsodium
and water in the kidneys (4 1). The net effect ofall ofthese actions is increased blood
pressure.

i _________

Angiotensinogen (agt)

Renin

Angiotensin I (Ang I)

I �-------- Angiotensin Converting

+
Angiotensin II (Ang II)

Enzyme (ACE)

.-----------I �-------.

0 thirst

ADH release,;

vasoconstriction

i blo:rvolume
�

/

aldosterone
release

i

�sorption

i blood pressure

Figure 1. RAS and its biological effects.
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Two ofthe commonly prescribed blood pressure medications function by
blocking the RA S. One inhibits A CE and blocks the conversion ofang I to ang II. The
other blocks an ang II receptor, preventing ang II from acting on target cells. Treatment
with both A CE inhibitors (such as captopril) and A T 1 receptor antagonists (such as
losartan) have been clinically shown to significantly reduce blood pressure (4 2- 46).

Ang II Receptors
Ang II acts through two main receptors: angiotensin II type 1 (A T 1) and type 2
(A T 2) receptors. Although several others have been reported, they are less studied
(3 9,47). Both receptors are G-protein coupled and have seven hydrophobic
transmembrane segments (37). The receptors have unique signaling and physiological
functions as well as different sites of expression (37,48). There is a 3 4 percent homology
between the amino acid sequences of the two receptors (4 9,50). The receptors are able to
be distinguished from each other according to their inhibition by specific receptor
antagonists (Figure 2). A T I receptors are selectively blocked by biphenylimidazoles such
as losartan, and A T 2 receptors are blocked by tetrahydroimidazopyridines such as PD
1 23,3 1 9 (PD), also called P- 186 (5 1- 5 4).
The A T I receptor is expressed in somatic and brain tissues, and located primarily
in the adrenal glands, vascular smooth muscle cells, kidney and heart (5 2). The
biological actions ofang II discussed earlier such as vasoconstriction, aldosterone
secretion, osmoregulation and sodium balance are mediated though the A T I receptor
(37,47,5 2,5 4,5 5).
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i-

agt

---remn
◄

ang I captopril

'--- A C E

i- x
◄

--

ang II
losa7

AT1

Figure 2. Antagonism of R A S.

The A T 1 receptor has two iso forms in the rat, A T IA and A T IB, which share 9 4%
homology (56,57). The A TIA iso form is found predominantly in the kidney, liver, lung
and vascular smooth muscle, whereas the A T 18 isoform is found predominantly in
adrenal and anterior pituitary glands (5 4). Through selective receptor inactivation in
knockout mice, researchers have determined that the A T I A receptor is responsible for the
systemic blood pressure effects ofang II (58-60).
Ang II binding at A T 1 receptors in blood vessels causes vasoconstriction and
increases blood pressure (6 1,6 2). In addition, the A T I receptor mediates the growth and
proliferation ofcardiac myocytes, causing cardiac hypertrophy independent ofblood
pressure (5 4). All of these effects contribute to the pathology ofhypertension.
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The AT 1 receptor has 5 different signaling mechanisms: activation of
phospholipase A2 (PLA2) , phospholipase C (PLC), phospholipase D (PLD), L-type
calcium (Ca2+) channels and inhibition of adenylate cyclase (AC) (reviewed in (54)).
Activation of PLC results in the formation of inositol 1,4,5 triphosphate (IP3) and
diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP2) . IP3 increases
intracellular Ca2+ and DAG activates protein kinase C (PKC), with the final effect of both
being vasoconstriction. The inhibition of AC also causes vasoconstriction by decreasing
levels of adenosine 3 ',5 '-monophosphate (cAMP), a vasodilator. Opening Ca2+ channels
also signals vasoconstriction and aldosterone production and release. The activation of
PLA2 releases arachidonic acid, which produces prostaglandins.
Until recently there was little known about the AT2 receptor. It was originally
distinguished from the AT 1 subtype by its resistance to sulfhydryl-reducing agents and
+

GTP and the inhibition of T-type (cytosolic) Ca2 channel currents (63-65). Unlike AT 1 ,
which is associated with many tissues, the AT2 receptor is predominantly found in fetal
tissues, developing brain, adrenal glands and ovarian follicles (49,64,66,67). The
expression of the AT2 receptor in these tissues suggests a role in growth and
development. The AT2 receptor is expressed almost exclusively in fetal tissues, but then
declines dramatically after birth (68,69). Expression of the AT2 receptor is upregulated
during times of injury, such as wound healing and vascular remodeling (52).
In general, the cardiovascular effects of the AT2 receptor seem to be functionally
opposite to those of AT 1 (70). For example, AT2 receptor knockout mice exhibit
increased blood pressure. A possible explanation is that the AT2 receptor regulates
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Table 4. Summary ofthe main fun ctions of A T 1 and A T 2 re ceptors.
AT 1

AT2

somati c and brain tissues

fetal tissue development

fluid-ele ctrolyte balan ce

cell proliferation

blood pressure regulation

cell differentiaion and development

vaso constri ction

ang 1ogenes 1s

aldosterone synthesis and se cretion

wound healing

renal sodium reabsorption

tissue regeneration

vasopressin se cretion

apoptosis

cardia c hypertrophy and contra ctility

vasodilation ?

.

.

vasodilation (7 1,7 2). However, when the A T 1 re ceptor is blo cked, the A T 2 re ceptor is
able to regulate vaso constri ction (37 ). Table 4 is a summary ofthe main fun ctions ofthe
A T 1 and A T 2 re ceptors (37,5 2,5 4,73,7 4 )
The A T 2 re ceptor is G-protein coupled, however it does not appear to fun ction by
the typical signaling pathway (3 9 ). Ang II binding at the A T 2 re ceptor inhibits guanylate
cy clase (G C ) a ctivity (7 5 ). This de crease in G C causes an A T 2 -mediated de crease in
cG M P levels (6 5 ).
Adipose Tissue RAS

In addition to the classi cal system des cribed earlier, there are several peripheral
tissues that contain their own lo cal RA S (76 ). Adipose tissue is one ofthese tissues,
having all ofthe components ne cessary to produ ce ang II lo cally (77,78). The produ cts of
adipose tissue RA S not only a ct dire ctly on adipose tissue, but also are able to contribute
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systemically to blood pressure regulation and kidney filtration (78, 79). This suggests that
this adipose tissue RAS plays an important role in obesity and obesity-related
hypertension.

Regulation of RAS

As the precursor to the RAS pathway, availability of agt is a major regulator of
the amount of ang II that is produced. Agt is produced in adipose tissue (77, 78,80) and
contributes to circulating agt levels (81). Proportionally elevated levels of agt are seen
with increased BMI (82,83), implying that agt production is directly related to amount of
adipose tissue. Adipose tissue is able to indirectly regulate agt circulating levels in part
through estrogen (81). Adipocytes produce estrogen which is able to bind hepatic
receptors to increase agt expression (81).
Agt mRNA is nutritionally regulated in adipose tissue. Both agt mRNA and
protein are decreased during fasting and increased with refeeding (80). Ang II, fatty
acids, adrenal glucocorticoids and insulin increase adipocyte-derived agt (7,84-86) Agt
mRNA is expressed in a differentiation-dependent manner (87). Stimulators of adipocyte
differentiation as well as lipogenic factors such as isobutylmethylxanthine,
dexamethasone, ethynylestradiol and T3 also increase agt mRNA levels (87,88).
Conflicting results have been reported regarding the effects of obesity on agt expression
(89). Expression of agt mRNA is decreased in obese adult Avy and fatty rats, but
increased in o b/ob and db/db mice and in young fatty rats (80,86,90). However, further
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studies are needed to determine if these differences are possibly due to the developmental
stage, mutation or sex (89,9 1 ).
Effects ofRAS
Endocrine effects

Adipocyte agt contributes to circulating levels of agt (79,80,92) and affects

systemic RAS functions. Massiera et al. reported increased fat mass and high blood
pressure in transgenic animals that over-express agt in adipose tissue (79). While

knockout mice exhibit low blood pressure, decreased adiposity and renal abnormalities,
re-expressing agt in these mice normalized fat mass as well as restored blood pressure

and renal functions of these animals (79). Recent studies from our lab confirmed these

changes in adiposity in the knockout and transgenic versus the control mice (93). This is
a prime example of the endocrine capacity of adipose tissue, which also establishes a

direct relationship between adipose tissue mass and hypertensive effects; hence, obesity

related hypertension.
Paracrine effects

In adipose tissue, ang II stimulates adipocyte growth and differentiation (94,95).

By using receptor antagonists, studies from our lab and others identified the AT2 receptor

as the predominant receptor expressed in adipose tissue (94,96). Furthermore, the effects
of ang II on adipocyte lipogenesis were shown to be mediated by the AT 2 receptor (96).
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Adipose tissue hyperplasia is regulated by ang I I in a paracrine manner: ang I I
stimulates the release ofprostacyclin (P G I 2 ) by mature adipocytes (94,97). The P G h
produced stimulates the differentiation ofpreadipocytes into adipocytes in ob 177 1 cells
(Figure 3) (94). Administering the A T 2 receptor antagonist blocked both the production
and lipogenic effects of P G h demonstrating that both ofthese actions are mediated by the
A T 2 receptor (94).
Hypertrophic growth ofthe adipocyte is also regulated via the A T 2 receptor. The
acti vities ofboth fatty acid synthase (F A S) and glycerol-3-phosphate dehydrogenase
(G PD H) are increased when ang I I binds at the A T 2 receptor (96). The net effect of
increasing these en zy me activities is triglyceride synthesis (Figure 3). Inhibition ofthe
A T 2 receptor by PD prevents these effects (96).

pr e a dipo cyt e

d i ffe re n t ia t i o n

i tr i gl yc er id e s
i l ip o g en e s i s
i FAS and G P D H
i AG T
i l e pt i n

p ro sta c y c l i n �
(P G 12)

Figure 3 . Summary of ang I I effects in adipose tissue via the A T 2 receptor.
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In tissues th at express both AT 1 and AT 2 receptors, the A T 2 receptor h as the
ability to function as an ant agonist by b inding directly to the AT 1 receptor and inh ibiting
its activ ation (98).
Un fortun ately the d at a on ang II receptors in adipose tissue is still sp arse and
sometimes controversi al. This is possibly due to v ari ance in receptor express ion and
activity depending on species, development al st age and nutrition al and hormon al st ates.
T able 5 is an overview ofresults thus far.
In summ ary, adipose tissue produces ang II as well as other lipogenic factors,
which in tum incre ase the amount of adipose tissue through both hypertrophy and
hyperpl asi a. This is a vicious circle th at ultim ately le ads to high blood pressure (Figure
4). Adipose tissue affects blood pressure vi a adipose tissue derived agt (A T 1 sign aling)
th at enters the bloodstre am (7 9) and also vi a the p ar acrine effects of ang II (A T 2
s ign aling).

Figure 4. Summ ary ofendocrin e and p ar acrine effects of adipose tissue
on blood pressure.

19
Table 5 . Current research on ang II receptor expression in adipose tissue.
receptor
expressed

animal
species

AT I

3T3-L l cell
line
rat

location of type of adipose preadipocyte
receptor
tissue
or adipocyte

adipocyte
membrane
adipocyte
membrane
adipocyte
membrane

rat (obese)

human
human
(obese)

adipocyte
membrane

epididymal,
mesenteric,
retroperitonal
brown and
white adipose
tissue

epididymal

omental or
subcutaneous

3T3-L l cell
line

Ob 1 77 1 cell
line

human

reference

preadipocyte
& adipocyte

?

( 99 )

adipocyte

?

( 1 00)

adipocyte

?

(101)

adipocyte

?

( 1 02)

adipocyte

regulate
adipocyte size

( 1 03)

adipocyte

age-dependent
hypertrophy

( 1 04) *

?

( 1 05)

.
.
mcrease m
cyclin D I

( 9 5)

adipocyte

?

(101)

adipocyte

up-regulation
of FAS and
GPDH

(96)

preadipocyte

?

( 99 )

whole adipose
subcutaneous,
tissue and
omental and
adipocyte
cultured
mammary
adipocytes
subcutaneous
whole adipose
upper
preadipocyte
tissue
abdominal
adipocyte
membrane

AT2

epididymal

function

preadipocyte differentiation
.
.
mcrease m
PGI2
adipocyte
production
pnmary
culture

adipocyte

?

( 94)
( 94)
(96) t

* This study showed a decrease in amount of AT 1 receptor mRNA; however there were
increased levels of AT 1 receptor protein. t Also unpublished data from our lab.
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CHAPTER III
EXPERIMENTAL SECTION:

DIFFERENTIAL EFFECTS OF ANGIOTENSIN II TYPE 2 RECEPTOR
ANTAGONISM ON ADIPOSITY IN MICE MODELS OF OBESITY

Introduction

With the discovery of a local RAS in adipose tissue, the importance of
understanding ang II effects becomes crucial in researching obesity-related hypertension
and other disorders. It is now well established that ang II increases adipocyte
differentiation (94) and lipogenic enzymes (96) in adipocytes and that this occurs via the
AT2 receptor. However, these findings have all been performed using in vitro studies.
The purpose of this research is to test these effects in vivo.
Preliminary studies from our lab explored the effects of ang II receptor
antagonists in lean, normal C57BL/6J mice (106). The animals lost weight and had
smaller fat pad weight and lower leptin levels when treated with AT2 antagonist PD vs.
vehicle. This experiment was repeated in a db/db obese mouse, to test the weight
reducing effect of PD in a genetically obese mice (106,107). Surprisingly, AT2
antagonism in these animals increased body weight and leptin levels. Both of these
studies were confirmed by primary culture of adipocytes from these mice where
treatment with the AT2 antagonist in adipocytes from lean mice reduced leptin secretion
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compared to vehicle and ang II treatment (106,107). Treatment with the AT2 antagonist

did not have an effect in the db/db mice (106,107). The db/ db mice have severe diabetes,
kidney disease and obesity, which may have played a role in these unexpected results. In

addition, the db/ db mouse is on a different genetic background than C57BL/6J, which
may be an additional confounding variable.

Research Objectives

Given the above-described studies from our lab, and the conflicting effect of PD

in lean vs. obese db/db mice, the goal of this thesis project was to further investigate the

effects of AT2 receptor antagonist in other mouse models of obesity. Specifically, we
propose the following aims:

1. Determine the effects of the ang II receptor antagonist in another genetic model of

obesity, the leptin deficient ob/ ob mice. The antagonist was administered in vivo to

these mice or used to treat primary adipocytes isolated from these animals. Due to

limited availability of ob/ ob mice, PD was the only drug used in this study.

2. Determine the effects of ang II antagonism in a non-genetic model of obesity, high-fat
diet induced obesity (DIO). This model more closely mimics human obesity. After

obesity is induced, mice are treated with the antagonist and switched to a chow diet
(DIO I ) or kept on a high-fat diet (DIO2). In addition, adipocytes from these obese
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mi ce were cultured in vitro to inve stigate the dire ct effe ct of the antagoni st. In
addition to the A T 2 antagoni st, the A T 1 antagoni st , losartan, and A CE inhibitor,
captopril were u sed in all DI O experiment s a s additional mean s to blo ck the action or
produ ction ofang II.

Experimental Design and Approach

Animals

Twenty- four 6-week-old male ob/ob mi ce (C 57BL /6 J ba ckground) were
pur cha sed from Ja ck son Lab s (Bar Harbor, ME). The animal s were maintained on a
chow diet throughout the experiment . A fter a one-week a cclimation period, mi ce were
divided into two group s, control (n = 1 2) and treatment (n = 1 2) group. The control group
wa s inje cted with pho sphate buffered saline (PB S). The treatment group wa s inje cted
with PD 1 23,3 1 9 ditrifluoroa cetate (PD) (Si gma, St. Loui s, M O) ( 1 5 mg /kg body weight)
di ssolved in PB S. The animal s were given sub cutaneou s inje ction s daily for 2 1 day s and
were sa crifi ced on day 22.

DI O I : Treatment of chow -fed mice
Twenty-nine 6 -week-old ma le C5 7BL/6 J mi ce we re purcha sed from Ja ck son Labs
(Bar Harbor, ME). The animal s were fed a high fat diet (4 5 k cal% fat) (D 1 24 5 1 ,
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Res earch D iets, N ew Brunsw ick, N J) for 10 w eeks to induc e ob es ity (S ee app end ix A -2
for d iet compos it ion). At th e start of inj ect ions, th e an imals w er e sw itch ed to chow d iet.
Th e an imals w er e d iv id ed into four groups: control (n =7), AT 1 antagon ist (n =7),
A T 2 antagon ist (n =8) and A CE inhib itor (n =7). Th e control group was inj ect ed w ith
PB S. Th e A T 1 antagon ist group was inj ect ed w ith losartan (M erck, Wh it ehous e Stat ion,
N J) (1 5 mg /kg body w eight). Th e A T 2 antagon ist group was inj ect ed w ith PD ( 1 5 mg /kg
body w eight). Th e A CE inh ib itor group was inj ect ed w ith captopr il (S i gma, St. Lou is,
M O) (0.6 25 mg /kg body w eight). All dr ugs w er e d issolv ed in PB S. Th e an imals w er e
g iv en subcutan eous inj ect ions da ily for 1 9 days and w er e sacr ific ed on day 20.

DI O 2: Tr eat ment ofh i gh -fat -fed mic e
Forty 6 -w eek -old C 57BL /6 J mic e w er e purchas ed fro m Jackson Labs (Bar
Harbor, ME). Th e an imals w er e fed a h igh fat d iet (4 5 kcal% fat) (D 1 24 5 1, R es earch
D iets, N ew Br unsw ick, NJ) for 1 2 w eeks to induc e ob es ity (S ee app end ix A -2 for d iet
compos it ion). Th e an imals r ema in ed on th e h igh -fat d iet throughout th e cours e ofthe
exp er iment.
Th e an imals w er e d iv id ed into four groups: control (n = 10), A T 1 antagon ist
(n = 10), A T 2 antagon ist (n = 10) and A CE inhib itor (n = 10). Th e dosag e of losartan for th e
A T 1 antagon ist group was incr eas ed to 30 mg /kg body w eight. Th e dosag e of PD for th e
A T 2 antagon ist group was also incr eas ed to 30 mg /kg body w eight.
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The dosage ofcaptopr il for the AC E inh ib itor group was increased to 1.25 m g/kg
body we ight. The drugs were d issolved in PB S and were g iven da ily by subcutaneous
inject ion.
Due to the large number ofan imals, halfthe an imals in each group were
sacr ificed a fter 2 1 days oftreatment and the other halfa fter 22 days. The an imals
sacr ificed on day 2 1 were injected for 20 days and the an imals sacr ificed on day 22 were
injected for 2 1 days.
An overv iew ofthe exper imental des ign can be found in F igure 5.
A dose response in lean and DI O m ice is ideal to determine the most effect ive
dose of P D. The dose chosen here took into the account the cost and ava ilab il ity of P D,
and the prev ious find ings from our lab and others ( 106 - 1 10).
Based on publ ished stud ies, the doses of both losartan and P D used in rodents
range from 5 to 50 mg/kg body we ight (108- 1 10). The dosages were chosen to be w ith in
th is range and were based on prev ious find ings from our lab us ing lean m ice where 1 5
mg/kg body we ight was su ffic ient to not ice s ign ificant decrease in body we ight and lept in
( 106, 107).
The prescr ibed dose ofcaptopr il for humans is 25 to 50 mg /day ( 1 1 1). Based on a
70 kg person, th is is 0.3 57 to 0.7 1 4 mg/kg body we ight. The lower dosage ofcaptopr il
used in the DI O 1 s tudy (0.6 25 mg/kg body we ight) is w ith in th is range and comparable to
what is prescr ibe d. The DIO2 dosage ( 1.25 mg/kg body weig ht) is a bove the norma l
range prescr ibed.

ob/ob

(n=24)

D101

(n=29)
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Figure 5. Overview of experimental design of animals studies. The animals were fed chCMt diet unless
otherwise specified. DIO f diet..induced obesity� HFD, high fat diet
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In all of the above studies the animals were given free access to food and water.
The environment was temperature controlled and on a 1 2 hour light /dark cycle.
The animals were randomized into groups such that the average weight in each group was
comparable. The animals were weighed twice a week and the amounts injected were
recalculated accordingly. The food was weighed daily . In cases when there were two or
more animals per cage, the food weight was averaged for each animal. Unless specified,
the animals were maintained on chow diet (86 40, Harlan, Madison, WI) (See appendix
A- 1 for diet composition).
All animals were fasted for 10 hours pr ior to sacr ifice . On the day of sacr ifice,
the animals were exsanguinated while under iso fluorine anesthesia. Blood was collected
by cardiac puncture. The following tissues were harvested: liver, kidney, epid idymal fat
pad, abdominal fat (perirenal and mesenteric fat pads), heart and brain. The liver and
adipose tissue samples were weighed at the time ofcollection. All tissues were snap
frozen in liquid nitrogen for further analysis.

Primary culture of adipocytes
D1 0 mice were sacrificed by the a forementioned procedure. Pr imary culture of
adipocytes was per formed as previously described ( 1 1 2). The adipose tissue was
removed and washed twice with Hanks . The tissue was cut into small pieces and divided
into culture dishes (100 mm or 3 5mm/6 well plates). The tissue was incubated with
DM EM m edia supp lemented with 1% B S A, 0. 1 % FB S, 1% penicillin /s tre ptomyc in and
0.5% gentamicin for 48 hours. T he med ia was r emov ed a fter 2 days and r epla ced with
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new media containing the following treatments: PB S, ang II ( l0n M), PD ( l00 µM) and
both ang II and PD. A fter two days ofincubation, the media was removed and frozen.
When applicable, fresh media along with the treatment was added and incubated another
day be fore both tissue and media were collected. The doses ofang II and PD used were
submaximal and were based on previous dose-response studies in our lab.

Glucose
Fasting blood glucose readings were taken at the time ofsacrifice. The whole
blood was measured using a

ONE TOUCH

Profile glucose meter (Life Scan, Milpitas, CA).

Leptin and Insulin Radioimmunoassay
Leptin and insulin concentrations were determined by radioimmunoassay (RIA).
The leptin was measured using a mouse leptin RIA kit from Linco Research (St. Charles,
M O). The leptin concentration was measured using 50 µL ofplasma for both DI O in
vivo studies and 100 µL ofmedia from the in vitro studies. The insulin was measured
usin g a rat insulin RIA kit from Linco Research (St. Char les, M O). Insu lin
concentrations were measured using 50 µL ofp lasma from both ofthe DI O in vivo
studies.
RIA kits measure hormone concentrations by quantifying the amount ofbinding
to a specific antibody. This is done by allowing the hormone and antibody to bind, and
then introducing a radiolabeled hormone. In this case the proteins were labeled with

1 25

1.

The radio-labeled hormone will bind to open sites on the antibody where the samp le has
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not bound. The rad ioact iv ity is measured on a gamma counter and there is an inverse
relat ionsh ip between the amount ofrad ioact iv ity present (in counts per m inute) and
hormone concentrat ion. Th is relat ionsh ip is graphed form ing a standard cur ve us ing
standard concentrat ions prov ided w ith the k it. The sample values are extrapolated based
on th is standard cur ve.

FAS and GPDH assays
The ep id idymal fat pads were homogen ized in 250 m M sucrose buffer conta in ing
protease inh ib itor, 0. 1 m M phenylmethanesul fonyl-fluoride (P M SF) and centr ifuged to
collect the cytosol ic fract ion. The act iv it ies ofF A S and G PD H were determ ined in
cytosol ic extracts by measur ing the rate of ox idat ion of NAD P H (for F AS assay) and
NAD H (for G PD H assay) ( 1 13). The ox idat ion rate was measured
spectrophotometr ically at 3 40nm. These numbers were corrected for prote in
concentrat ion.

Protein assay
Prote in concentrat ion was determ ined by the Brad ford assay ( 1 1 4). The dye used
for th is assay, Coomass ie blue (B io -Rad), is a red-brown that absorbs l ight at 470nm.
When the dye b inds to prote in, the color changes to blue and the absorpt ion wavelen gth
sh ifts to 5 9 5nm.
Each sample was done in dupl icate w ith 10 µL sample and 200 µL ofdye be in g
comb ined in a 96 -well plate . After a 5 m inute incubat ion, the plate was read at 5 90nm.
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A standard curve was created using dilutions ofbovine serum albumin (B S A) at known
concentrations. The sample concentrations were extrapolated based on this standard
curve.

RNA isolation
RNA was extracted from abdominal fat pads by homogenizing adipose tissue in
guanidine isothiocyanate (G T C) (lnvitrogen, Carlsbad, CA) containing 7% �
mercaptoethanol and purified using the cesium chloride density gradient method ( 1 1 5).
The RNA was further purified using phenol /chloro fo rm (Ambion, Austin, TX) followed
by ethanol precipitation. RNA was resuspended in 0. 1 T E and stored at -80 ° C until
further analysis.

Real time PCR
Expression ofF A S m RN A was determined using real time P C R (1 16). This
probe-based P C R product detection was used to quantify RNA concentration from a
standard curve that was obtained using total RNA.
Real time P C R was used because it is more sensitive that a Northe rn blot and can
quickly and accurately quantify concentrations of R N A. During the P C R reaction, the
probe binds specifically to the target sequence. The probe has a fluorescent reporter dye
and quencher dye that, when in close proximity, reduces the fluorescence ofthe reporter.
The probe is cleaved by Taq polymerase at the 5 ' end when the primer is extended. This
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cleavage separates the reporter from the quencher, which increases the signal of the
reporter.
The primers and probe were ordered from Sigma Genosys (The Woodlands, TX).
The sequence of the forward primer is 5' CCCAGAGGCTTGTGCTGACT 3'. The
sequence of the reverse primer is 5' CGAATGTGCTTGGCTTGGT 3'. The sequence of
the probe is 5' (TET)CCGATCTGGAATCCGCACCGG(TAMRA) 3 '. The SmartCycler
software (Cepheid, Sunnyvale, CA) was programmed as indicated in Table 6.

Statistical analysis

Statistical analysis was done in SPSS (SPSS for Windows, Rel. 11.0.1.2001.
Chicago: SPSS Inc.) The data was analyzed using either a one-way analysis of variance
(ANOVA) or t-test. Tukey's HSD post-hoc analysis was used to determine differences
between groups if the ANOVA was significant (117). A 95% confidence interval was
used in determining significance in all tests. All data is expressed as mean ± SD.

Table 6. Cycles of real time PCR.
stage

temperature

seconds

number of
cycles

2
3

48 °C
95 ° c
95 ° c
60 °C

1,800
600
15
60

1
40
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Results

Effects of ang II antagonism in ob/ob mice

Treatment with PD lowered abdominal fat pad weights (p<0.001) and decreased
FAS activity (p<0.03) in ob/ob mice (Figure 6). There was no difference in FAS mRNA
concentration with treatment of PD. It is worth noting that gene expression was
measured in epididymal fat pads, which was not responsive to PD. There was no change
in body weight at the end of treatment, amount of weight gained over the course of
treatment, food intake per day, blood glucose, epididymal fat pad weight or GPDH
activity in PD-treated mice vs. control (Table 7 and Figure 7).

Effects of ang II antagonism in DIO1 mice maintained on chow diet

Treatment with PD decreased blood glucose levels in the DIOl mice compared to
control mice (p<0.03) (Table 8). Captopril also decreased blood glucose but this effect
did not reach significance (p=0.075). In addition, at the end of treatment, there was no
difference in body weight, amount of weight lost over the course of treatment, food
intake per day, fat pad weights, leptin levels, insulin levels, FAS or GPDH activity
between PD and vehicle groups (Figure 8).

Effects of ang II antagonism in D/02 mice maintained on high-fat diet

DIO2 mice treated with PD lost more weight over the entire treatment period than
all other groups (p<0.01) (Figure 9). Food intake was higher in mice treated with
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Tabl e 7 . Eff ects ofan g II anta gonism in ob/ob mic e.

control
(n = l 2)

PD
(n = l 2)

5 5. 1 ± 2.8

5 5.5 ± 2.7

4. 1 ± I. I

3.6 ± 1.2

food intak e/day (g)

5.8 ± 0.4

5.9 ± 0.3

blood glucos e (m g/dL)

266 ± 6 9

266 ± 6 1

epididymal fat pad (g)

4.5 ± 0.6

4.2 ± 0.4

G P DH activity (nmol
N A D H/min/m g prot ein) m easur ed
in epididymal fat pad

4.5 2 ± 2.6 4

5.38 ± 1.08

FA S mRNA conc entrat ion (n g/µL)
m easur ed in abdominal fat pad

1 4.98 ± 1.0 9

18. 1 9 ± 1.0 4

body w ei ght (g) at th e end of
tr eatment
w ei ght gai n (g) ov er cours e of
tr eatm ent

33
15
14
13
12
11

mJ abdominal fat
pad weight
(grams)

10

8

7

■F(nmo
A S activity
l/NADPH
/min/mg
protein)

6
5
4
3 --2

control

PD

* significantly di fferent from respective controls (p <0.0 5)
Figure 6. Effects of AT2 receptor antagonism on abdominal fat pad weight and F A S
activity in ob/ob mice.
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Table 8. Effects ofa ng II anta gonists in DI O I mice.

control
(n =7)

losartan
(n =7)

PD
(n =8)

captopril
(n =7)

body wei ght (g) at the
end oftreatment

3 1.7 ± 2.0

3 1 .5 ± 2.1

3 2.4 ± 2. 1

3 1.8 ± 2.0

wei ght loss (g) over the
course of treatment

3.0 ± 1.7

3.0 ± 2.2

2.7 ± 2. 1

3. 1 ± 1.8

food intake /day (g)

4.3 ± 0.5

4.4 ± 0 .5

4.5 ± 0.6

4.6 ± 0.5

blood glucose (m g/dL)

20 5 ± 28b

186 ± 1 1 6 a,b

1 67 ± 23 a

173 ± 26 a,b

epididymal fat pad (g)

0 .8 ± 0.3

0.7 ± 0.4

0.8 ± 0 .3

0.8 ± 0.3

abdominal fat pad (g)

0.7 ± 0.4

0.6 ± 0.3

0.7 ± 0.3

0.6 ± 0.3

leptin (n g/mL)

4.9 1 ± 2.0 5

3.27 ± 0.6 6

5.37 ± 2.03

3.9 1 ± 1.3 2

insulin (n g/mL)

0.90 ± 0.5 2

0.66 ± 0. 1 9

0.8 1 ± 0.3 4

0.58 ± 0.2 1

F A S activity (nmol
NAD P H /min /m g
protein) measured in
epididymal fat pad

2.0 6 ± 0.87

1.29 ± 0.70

1.27 ± 0.85

1.30 ± 0. 5 5

G PD H activity (nmol
NA D H/min/m g protein )
measured in epididymal
fat pad

3.60 ± 0.7 5

5.27 ± 4.0 4

3.0 2 ± 1.4 5

3.63 ± 1. 1 5

Values with the different letters are si gnificantly different (p <0.0 5 ). Values with the
same letter are not significantly different.
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losartan vs. PD (p<0.0 1), and was also higher in losartan (approached significance,
p =0.0 56) compared to vehicle-treated mice (Figure 10). At the end oftreatment, there
was no difference in body weight, blood glucose, fat pad weights, leptin, insulin, F A S or
G PD H activity between any ofthe groups ofmice (Table 9).

Effects of a ng II a nd PD in prim ary a d ipo cyt es
When primary adipocytes from DI O mice were treated with ang II there was no
change in leptin secretion (Table 10). There was also no effect with PD treatment alone
or with ang II and PD in combination.

Discussion

Our lab has previously shown that blocking the A T 2 receptor decreases fatty acid
and triglyceride synthesis in cultured 3 T3-Ll adipocytes (96). In addition, Darimont et
al. demonstrated that the A T 2 receptor mediated ang II-induced P G b release and
adipocyte differentiation in cultured ob 177 1 adipocytes (94). In agreement with these
findings, pilot studies from our lab demonstrated that the A T 2 receptor antagonist,
PD 1 23,3 1 9, decreased weight gain, fat pad weight and plasma leptin in lean C 57 BL/6 J
mice, while in db/db mice, PD increased we ig ht gain and pla sma leptin leve ls ( 106, 107).
The obser vations indicate that the A T 2 r eceptor mediat es ang II effects on adipose tissue
metabolism.
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Table 9 . Effects ofang II antago nism in DI O 2 mice .

control
(n =l 0)

losartan
(n =l0)

PD
(n = I O)

captopril
(n =l O)

blood glucose (mg /dL)

1 92 ± 54

225 ± 3 5

203 ± 37

199 ±35

epidid ymal fat pad (g)

1. 1 ± 0.5

0 .9 ± 0.4

0.8 ± 0 .4

1.2 ± 0.7

abdominal fat pad (g)

0.9 ± 0.4

0 .5 ± 0.3

0.6 ± 0.4

0.9 ± 0.6

leptin (ng/mL)

8.28 ± 5.7 2

4.36 ± 2. 1 5

5 .76 ± 4.88

9.38 ± 7 . 1 4

insulin (ng /mL)

0 .6 5 ± 0.80

1.00 ± 1. 17

0.60 ± 0.7 5

0.6 1 ± 0.36

2. 1 4 ± 0.63

2.0 1 ± 0.80

1.85 ± 0.66

2.3 1 ± 0.9 1

3.7 4 ± 1.84

2.6 4 ± 1.6 4

2.4 2 ± 1 .8 2

2.0 2 ± 1.47

F A S activity (nmol
NAD P H/min /mg protein)
measured in epidid ymal
fat pad
G PD H activity (nmol
NAD H /min /mg protein)
measured in epidid ymal
fat pad

Ta ble 10 . Effects ofang II and PD on leptin secreted from adipocytes ofDI O mice.

leptin (ng/mL)

control

ang II

PD

ang II + PD

5.6 5 ± 3.7 2

5 .4 4 ± 3 .4 5

4.60 ± 2.84

5.83 ± 3.5 4
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Figur e I0. Effects ofang I I antagonists on food intake in D1 02 mi ce.
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In this study, consistent with findings from Jones et al (96) in cultured adipocytes,
we found that FAS activity in epididymal fat pad decreased with PD treatment in o b/ob
mice, however, fat pad weight was unaffected. Gene expression was quantified using
mRNA isolated from the abdominal fat pads, which were smaller with PD treatment;
however, FAS mRNA content in this tissue was not affected by PD. The entire
epididymal fat pad was used for enzyme activity assays; therefore we were unable to
measure gene expression to determine if the decrease in activity correlates with change in
FAS mRNA concentration.
The decrease in blood glucose with PD treatment in the DIOl study is supported
by recent studies demonstrating increased insulin sensitivity and decreased
hyperinsulinemia with ang II antagonism ( 118-120). However there was no change in
insulin levels at the time of sacrifice in our mice. Furthermore, there was no change in
blood glucose or insulin levels in mice from DIO2 study.
Treatment with PD did not affect weight loss in the DIOl mice, but did cause
weight loss in the DIO2 mice. This could be due to the increased dosage of PD (30
mg/kg body weight) in the second study, or possibly the effect of PD was masked in the
first study by the weight loss associated with changing the high fat diet to the chow diet
at the start of treatment. In all studies, regardless if the mice were gaining or losing
weight, the body weight of the mice decreased over the last interval of measurement
independent of treatment (Figures 7, 8, 9).
The only obese animals that exhibited a significant reduction in body weight were
the DIO2 mice maintained on a high fat diet during AT2 antagonist treatment. In the
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DI O 2 study, mice treated with losartan ate more, however, the body weight at the end of
treatment is not different from other groups. This could be due to increased activity in
these mice as blocking ang II production in agt knockout mice has been shown to
increase locomotor activity in these mice ( 1 2 1). Although not measured in this study, we
observed more aggression and activity in all drug -treated animals. In future studies it
would be more in formative to measure metabolic activity ofthese mice.
Several studies have determined that ang II increases leptin secretion in
adipocytes in culture (93, 106, 107). Previous studies in our lab have reported that
treatment with P D decreased leptin secretion below t he control levels in lean mice
( 106, 107). In the in vitro study per formed here, P D had no effect on leptin secretion
from adipocytes of DI O mice. The former studies used 3 T3-Ll and human adipocytes
(93) while in our current studies we used primary culture ofmouse adipocytes.
In part, our findings support the results from the lean mice study in that some
metabolic parameters were decreased in ob/ob and DI O mice upon treatment with P D;
however, not all parameters were consistently affected. However, none ofthe obese
models in this study have replicated the increase in adiposity and leptin in the db/ db mice.
The background strain ofthe db/ db mouse is C 57BL KS/J and is different from the
C 57BL /6 J background ofthe lean, ob/ob and DI O mice. The unexpected effect of P D in
db/ db mice may be due to the background strain, genetic mutation, diabetes or kidney
disease in these animals.
In using antagonists to block RAS, the expected result, based primarily on in vitro
studies, is decreased fat pad mass via decreased adipocyte metabolism (9 5,96). In
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addition, insulin secretion would be lowered and thus decrease its effect on agt
expression (86), further depressing this system. There is some evidence of these actions
in the in vivo studies. However, there was no overall or consistent effect of ang II
antagonism in the different models of mice obesity used in this and previous studies by
our lab. It is possible that statistical significance may have been achieved in more
parameters if the sample size had been larger for each group. However significant and
dramatic changes were previously seen in lean mice with only 6 to 8 mice in each group,
using the lower dosage of the drugs. It is possible that in an obese mouse there is an
increased variability in the effects of ang II antagonism and possibly requires a larger
dosage to see an effect. Alternatively, the responsiveness of obese mice may reflect the
intrinsic properties of the adipocyte, the level of obesity, diabetes, insulin and leptin
resistance in these models, which may counteract the weight reducing effect of PD. Just
as many obese mice are resistant to insulin or leptin, it is possible that obese mice are
resistant to the effects of ang II in adipose tissue.

Summary and Conclusions

The goal of these studies was to confirm in vivo the weight reducing effects of
RAS blockade. The overall results demonstrate that RAS inhibition does decrease some
symptoms of the metabolic disorder of obesity. We did see a decrease in weight and FAS
activity in ob/ob mice and weight and blood glucose levels in D10 mice, however the
results were inconsistent in the different mouse models of obesity and between normally
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coordinated parameters (such as glucose and insulin). Additional studies are needed to
con firm the effects of P D in obese mice . However, our findings in ob/ ob and DI O mice
are consistent with a potential role ofthe AT 2 receptor in adipocyte metabolism and
energy re gulation .
The inconsistencies in responsiveness in the above metabolic parameters
measured in lean vs. obese mice demonstrate the complexity and multi-factorial nature of
the system being studied. Variability among individuals is inherent to an in vivo study
and metabolic al terations associated with obesity are additional con founding factors.
The importance ofthis research is very signi ficant, however, as R AS has many
links to the metabolic syndrome ofobesity and related disorders. This thesis mainly
focused on blockade ofthe adipocyte R AS and the potential ofimproving both obesity
and hypertension, which are closely linked.
In conclusion, blocking ang II reduces hypertension in two ways (fi gure 1 1): by
decreasing systemic effects of R AS and by inhibiting the excess contribution ofadipose
tissue to ang II production.
In many cases ofhypertension where obesity is the cause, these findings
constitute a preliminary step to develop treatments for obesity-related disorders that more
speci fically target the AT 2 receptor instead ofblocking the entire R AS. This approach
would reduce the disruption in systemic functions by targeting adipose tissue. This
would be especially important in cases ofobesity without hypertension that did not
require a systemic blockage of R AS. However, further studies are warranted to ascertain
the effects ofang II receptors in mice be fore clinical trials can be undertaken.
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Ang il

systemic/circulation
(endocrine)
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Figure 1 1. Contribution of adipocyte ang II to obesity and hypertension.

Finally, as with any pharmacological treatment of obesity, AT2 receptor

antagonism if proven effective in vivo, should be used in conjunction with behavioral
therapy including diet and physical activity to reduce weight and adiposity.
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Table A- 1 . Compos it ion ofchow d iet. Harlan Teklad 22/5 Rodent Diet (W) 86 40.
www.teklad.com /rodent/standard /86 40.htm

.
G uaran teed A na I1ys1s
Crude Protein
Crude Fat
Crude Fiber

22.0% min.
5.0% min.
4.5% max.

A vera2e N utrient C ompos1tion
Protein
Fat
Fiber
Ash
Nitrogen-Free Extract
Gross Energy
Digestible Energy
Metabolizable Energy
Linoleic Acid

22.58%
5 .23%
3.94%
7.06%
5 1 . 1 9%
3 .82 kcal/g
3.38 kcal/g
3 . 1 1 kcal/g
3 .32 kcal/g

Amino Acids
Arginine
Methionine
Cystine
Histidine
Isoleucine
Leucine
Lysine
Phenylalanine +Tyrosine
Threonine
Tryptophane
Valine

1 .65%
0.37%
0.37%
0.52
1.17
1 .88%
1 .29%
2.04%
0.93%
0.29%
1 . 1 7%

Minerals
Calcium
Phosphorus
Sodium
Chlorine
Potassium
Magnesium
Iron
Manganese
Zinc
Copper
Iodine
Cobalt
Selenium
Vitamins
Vitamin A
Vitamin D3
Vitamin E
Choline
Niacin
Pantothenic Acid
P ridoxine
Riboflavin
Thiamine
Menadione
Folic Acid
Biotin
Vitamin B 12
Vitamin C

1 . 1 3%
0.94%
0.40%
0.67%
1 .00%
0.24%
348.75 mg/kg
1 04. 1 9 mg/kg
78.84 mg/kg
24.07 mg/kg
2.69 mg/kg
0.72 mg/kg
0.26 mg/kg
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Table A-2. Composition of high-fat diet. Research Diets Rodent Diet D12451.
www .researchdiets.com

gm
24%
41%
24%
4.7

kcal
20%
35%
45%

Casein, 80 Mesh
L-Cystine
Com Starch
Maltodextrin 10
Sucrose
Cellulose, BW200
Soybean Oil
Lard
Mineral Mix S10026
DiCalcium Phosphate
Calcium Carbonate

200
3
72.8
100
172.8
50
25
177.5
10
13
5.5

800
12
291
400
691
0
225
1598
0
0
0

Potassium Citrate, 1 H 2 0
Vitamin Mix V l 000 l
Choline Bitartrate
FD&C Red Dye #40

16.5
10
2
0.05

0
40
0
0

Protein
Carbohydrate
Fat
kcal/gm
I ngre d"1ent
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